Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
2Seventy Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TSVT
Nasdaq
8731
https://www.2seventybio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for 2Seventy Bio Inc
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
- May 8th, 2024 11:00 am
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
- May 3rd, 2024 11:00 am
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
- Apr 5th, 2024 1:05 pm
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
- Apr 1st, 2024 11:30 am
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
- Mar 20th, 2024 9:04 pm
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
- Mar 15th, 2024 10:27 pm
Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term
- Mar 7th, 2024 11:16 am
When Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit?
- Mar 6th, 2024 11:13 am
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
- Mar 5th, 2024 12:00 pm
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
- Mar 1st, 2024 12:00 pm
2seventy bio to Participate in Upcoming Investor Conferences
- Feb 5th, 2024 9:05 pm
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
- Feb 5th, 2024 11:59 am
2seventy bio Announces New Strategic Path Forward
- Jan 30th, 2024 12:01 pm
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
- Dec 12th, 2023 12:30 am
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
- Dec 11th, 2023 12:00 pm
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
- Dec 6th, 2023 7:00 pm
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
- Nov 20th, 2023 11:59 am
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
- Nov 14th, 2023 12:00 pm
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
- Nov 10th, 2023 12:00 pm
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
- Sep 12th, 2023 11:00 am
Scroll